Gsk plc (GSK) Hedge Fund Ownership (Q2 2026)

Q: Is it too late to buy Gsk plc (GSK) following the 2026 Q2 hedge fund 13F filings?

As of today, GSK has moved -2.8% since the 2026 Q2 13F filing date (August 14, 2026), compared to -1.2% for the XLV sector ETF — an outperformance of -1.6%. Since the quarter end (June 30, 2026), GSK gained -8.2% vs +4.2% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Gsk plc (GSK)

1K + Investors. Track Smart Money conviction in GSK. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — GSK

Based on 1052 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 6 quarters in a row

last 6Q

For 6 consecutive quarters, more hedge funds added GSK than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

1,052 hedge funds hold GSK right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

📶

Steady growth — +20% more funds vs a year ago

fund count last 6Q

+178 new funds entered over the past year (+20% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.

🟡

Slight buying edge — 52% buying

499 buying452 selling

Last quarter: 499 funds bought or added vs 452 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

⚠️

Fewer new buyers each quarter (-32 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 109 → 184 → 150 → 118. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔒

66% of holders stayed for 2+ years

■ 66% conviction (2yr+) ■ 16% medium ■ 18% new

693 out of 1,052 hedge funds have held GSK for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

➡️

Steady discovery — ~118 new funds/quarter

114 → 109 → 184 → 150 → 118 new funds/Q

New funds entering each quarter: 109 → 184 → 150 → 118. Consistent flow of new institutional buyers without clear acceleration or slowdown.

🏛️

Veteran-anchored — 70% veterans vs 22% newcomers

■ 70% veterans ■ 9% 1-2yr ■ 22% new

Entry-cohort mix of 1,076 holders: 748 (70%) are 2+ year veterans, 93 entered 1–2 years ago, and 235 (22%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

🏆

Elite ownership — 78% AUM from top-100 funds

78% from top-100 AUM funds

52 of 1041 holders are among the 100 largest funds by AUM, controlling 78% of total institutional value in GSK. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

3.7

out of 10

Low Exit Risk

Exit risk score 3.7/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	1038	1039	-0.1%
13F Shares	351M	379M	-7.24%
Total Value	$17.10B	$19.16B	-10.73%
New Positions	118	150	-32
Increased Positions	372	320	+52
Closed Positions	108	104	+4
Reduced Positions	341	378	-37
Total Calls	17	15	13.33%
Total Puts	14	14	-
PUT/CALL Ratio	0.82	0.93	Neutral

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

1038

1039

-0.1%

13F Shares

351M

379M

-7.24%

Total Value

$17.10B

$19.16B

-10.73%

New Positions

118

150

-32

Increased Positions

372

320

+52

Closed Positions

108

104

Reduced Positions

341

378

-37

Total Calls

13.33%

Total Puts

PUT/CALL Ratio

0.82

0.93

Neutral

Institutional Holders (2026 Q2)

1K + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in GSK. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 GSK holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Transmarket Holdings LP	7.25%	188,473	$9.9M
2	SALT Holding Corp.	6.54%	235,459	$12.3M
3	Mondrian Investment Partners LTD	3.97%	4,910,830	$257.4M
4	Sio Capital Management, LLC	3.79%	436,700	$22.9M
5	Hillman Capital Management, Inc.	3.51%	92,383	$4.8M
6	Callodine Capital Management, LP	3.35%	979,740	$51.4M
7	Equity Investment Corp	3.27%	3,269,765	$171.4M
8	Abc Arbitrage SA	3.05%	538,873	$28.2M
9	Keystone Financial Planning, Inc.	2.64%	195,590	$10.3M
10	Nia Impact Advisors, LLC	2.63%	121,036	$6.3M
11	Thomasville National Bank	2.51%	871,467	$45.7M
12	Keating Investment Counselors Inc	2.40%	166,818	$8.7M
13	Brentview Investment Management LLC	2.22%	106,846	$5.6M
14	Clean Yield Group	2.06%	158,720	$8.3M
15	Farringdon Capital, Ltd.	2.05%	78,744	$4.1M
16	Altrius Capital Management Inc	2.04%	204,447	$10.7M
17	Capricorn Fund Managers Ltd	1.76%	426,416	$22.4M
18	Figure 8 Investment Strategies LLC	1.71%	38,686	$2.0M
19	Twin City Private Wealth, LLC	1.68%	45,434	$2.4M
20	Miller Howard Investments Inc /Ny	1.64%	1,182,068	$62.0M
21	Arjuna Capital	1.60%	135,511	$7.1M
22	Walled Lake Planning & Wealth Management, LLC	1.59%	119,866	$6.3M
23	Kahn Brothers Group Inc	1.58%	160,982	$8.9M
24	Parrish Capital LLC	1.50%	29,610	$1.6M
25	Stockman Wealth Management, Inc.	1.43%	264,689	$13.9M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Gsk plc (GSK)

What does the Smart Money Trend signal show for GSK?

Buying streak — 6 quarters in a row: For 6 consecutive quarters, more hedge funds added GSK than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for GSK?

Slight buying edge — 52% buying: Last quarter: 499 funds bought or added vs 452 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for GSK holders?

Elite ownership — 78% AUM from top-100 funds: 52 of 1041 holders are among the 100 largest funds by AUM, controlling 78% of total institutional value in GSK. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held GSK?

66% of holders stayed for 2+ years: 693 out of 1,052 hedge funds have held GSK for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Gsk plc (GSK) following the 2026 Q2 hedge fund 13F filings?

As of today, GSK has moved -2.8% since the 2026 Q2 13F filing date (August 14, 2026), compared to -1.2% for the XLV sector ETF — an outperformance of -1.6%. Since the quarter end (June 30, 2026), GSK has gained -8.2% vs +4.2% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Gsk plc (GSK)

Smart Money Signals — GSK

Buying streak — 6 quarters in a row

At the ownership peak (100% of max)

Steady growth — +20% more funds vs a year ago

Slight buying edge — 52% buying

Fewer new buyers each quarter (-32 vs last Q)

66% of holders stayed for 2+ years

Steady discovery — ~118 new funds/quarter

Veteran-anchored — 70% veterans vs 22% newcomers

Elite ownership — 78% AUM from top-100 funds

Institutional Sentiment Summary — GSK

Hedge Fund Ownership: GSK

Market Analysis: GSK

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: GSK

Is It Too Late to Buy Gsk plc (GSK) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: GSK

Statistics: GSK

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Gsk plc (GSK)

Welcome to 13Foresight!